Artera Acquired | Healthcare M&A Deal

Artera has completed the acquisition of Artera, a diagnostics imaging business in California, for $90 million. Artera develops AI diagnostics imaging tools that use digital pathology histopathology images and clinical variables to predict distant metastasis risk in early-stage, hormone receptor-positive, HER2-negative invasive breast cancer. The platform stratifies patients into low- and high-risk groups to support treatment decisions on adjuvant endocrine therapy versus chemotherapy, including settings where genomic assays are costly or slow. The healthcare M&A deal is tied to FDA clearance for ArteraAI Breast and follows Artera’s prior de novo authorization for an AI prostate cancer tool, with the company reporting the clearance in 2026.